PG F2alpha receptor: a promising therapeutic target for cardiovascular disease
Prostaglandins (PGs), a group of key lipid mediators, are involved in numerous physiological and pathological processes including inflammation and cardiovascular homeostasis. Each PG acts on its specific and distinct cell surface G protein coupled receptors (GPCR) or peroxisome proliferator-activate...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2010-10-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | http://journal.frontiersin.org/Journal/10.3389/fphar.2010.00116/full |
id |
doaj-eff1d138bf094974b28147434379a076 |
---|---|
record_format |
Article |
spelling |
doaj-eff1d138bf094974b28147434379a0762020-11-24T21:18:35ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122010-10-01110.3389/fphar.2010.001161871PG F2alpha receptor: a promising therapeutic target for cardiovascular diseaseJian Zhang0Yanjun Gong1Ying Yu2Chinese Academy of SciencesChinese Academy of SciencesChinese Academy of SciencesProstaglandins (PGs), a group of key lipid mediators, are involved in numerous physiological and pathological processes including inflammation and cardiovascular homeostasis. Each PG acts on its specific and distinct cell surface G protein coupled receptors (GPCR) or peroxisome proliferator-activated receptors (PPARs). Prostaglandin F2aphar receptor (FP) is required for female reproductive function such as luteolysis and parturition. It has recently been implicated in blood pressure regulation, atherosclerosis and other inflammation-related disorders. The emerging role of FP in cardiovascular diseases is highlighted and potential therapeutic translation is discussed in the current review.http://journal.frontiersin.org/Journal/10.3389/fphar.2010.00116/fullAtherosclerosisHypertensionFP receptorProstaglandin F2alphar |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Jian Zhang Yanjun Gong Ying Yu |
spellingShingle |
Jian Zhang Yanjun Gong Ying Yu PG F2alpha receptor: a promising therapeutic target for cardiovascular disease Frontiers in Pharmacology Atherosclerosis Hypertension FP receptor Prostaglandin F2alphar |
author_facet |
Jian Zhang Yanjun Gong Ying Yu |
author_sort |
Jian Zhang |
title |
PG F2alpha receptor: a promising therapeutic target for cardiovascular disease |
title_short |
PG F2alpha receptor: a promising therapeutic target for cardiovascular disease |
title_full |
PG F2alpha receptor: a promising therapeutic target for cardiovascular disease |
title_fullStr |
PG F2alpha receptor: a promising therapeutic target for cardiovascular disease |
title_full_unstemmed |
PG F2alpha receptor: a promising therapeutic target for cardiovascular disease |
title_sort |
pg f2alpha receptor: a promising therapeutic target for cardiovascular disease |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Pharmacology |
issn |
1663-9812 |
publishDate |
2010-10-01 |
description |
Prostaglandins (PGs), a group of key lipid mediators, are involved in numerous physiological and pathological processes including inflammation and cardiovascular homeostasis. Each PG acts on its specific and distinct cell surface G protein coupled receptors (GPCR) or peroxisome proliferator-activated receptors (PPARs). Prostaglandin F2aphar receptor (FP) is required for female reproductive function such as luteolysis and parturition. It has recently been implicated in blood pressure regulation, atherosclerosis and other inflammation-related disorders. The emerging role of FP in cardiovascular diseases is highlighted and potential therapeutic translation is discussed in the current review. |
topic |
Atherosclerosis Hypertension FP receptor Prostaglandin F2alphar |
url |
http://journal.frontiersin.org/Journal/10.3389/fphar.2010.00116/full |
work_keys_str_mv |
AT jianzhang pgf2alphareceptorapromisingtherapeutictargetforcardiovasculardisease AT yanjungong pgf2alphareceptorapromisingtherapeutictargetforcardiovasculardisease AT yingyu pgf2alphareceptorapromisingtherapeutictargetforcardiovasculardisease |
_version_ |
1726008375833001984 |